RNA Interference Therapeutics for Tumor Therapy: Promising Work in Progress

Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition

Volumn , Issue , 2013, Pages 393-408

  Tsujiuchi, Takashi ^a   Miller, Andrew D ^b,c   Wakabayashi, Toshihiko ^a   Natsume, Atsushi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GlobalAcorn Ltd   (United Kingdom)

Author keywords

ABCD nanoparticle; Convection enhanced delivery (CED); Genetically modified T cell therapy; Malignant glioma; RNA interference (RNAi); Short hairpin RNA (shRNA); Temozolomide (TMZ)

Indexed keywords

EID: 84904082355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394295-1.00027-5     Document Type: Chapter

References (151)

1. Dykxhoorn D.M., Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005, 56:401-423.
2. Dykxhoorn D.M., Lieberman J. Knocking down disease with siRNAs. Cell 2006, 126(2):231-235.
3. Dykxhoorn D.M., Lieberman J. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng 2006, 8:377-402.
4. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006, 13(6):541-552.
5. Kato T., Natsume A., Toda H., Iwamizu H., Sugita T., Hachisu R., et al. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 2010, 17(11):1363-1371.
6. Okamoto S., Mineno J., Ikeda H., Fujiwara H., Yasukawa M., Shiku H., et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 2009, 69(23):9003-9011.
7. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978, 75(1):280-284.
8. Stephenson M.L., Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978, 75(1):285-288.
9. Zamecnik P.C., Goodchild J., Taguchi Y., Sarin P.S. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA 1986, 83(12):4143-4146.
10. Braasch D.A., Corey D.R. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 2002, 41(14):4503-4510.
11. Guo S., Kemphues K.J. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 1995, 81(4):611-620.
12. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391(6669):806-811.
13. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101(1):25-33.
14. Hutvagner G., Zamore P.D. RNAi: nature abhors a double-strand. Curr Opin Genet Dev 2002, 12(2):225-232.
15. Gil J., Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 2000, 5(2):107-114.
16. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411(6836):494-498.
17. Bratkovic T., Rogelj B. Biology and applications of small nucleolar RNAs. Cell Mol Life Sci 2011, 68(23):3843-3851.
18. Collins L.J. Characterizing ncRNAs in human pathogenic protists using high-throughput sequencing technology. Front Genet 2011, 2:96.
19. Holley C.L., Topkara V.K. An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovasc Drugs Ther 2011, 25(2):151-159.
20. Makarova J.A., Kramerov D.A. SNOntology: myriads of novel SnoRNAs or just a mirage?. BMC Genomics 2011, 12(1):543.
21. Scott M.S., Ono M. From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie 2011, 93(11):1987-1992.
22. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011, 12(12):861-874.
23. Antoniades H.N., Galanopoulos T., Neville-Golden J., Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; In vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992, 50(2):215-222.
24. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994, 54(8):2218-2222.
25. Weller M., Fontana A. The failure of current immunotherapy for malignant glioma: tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995, 21(2):128-151.
26. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003, 21(1):21-32.
27. Rudnick S.I., Swaminathan J., Sumaroka M., Liebhaber S., Gewirtz A.M. Effects of local mRNA structure on posttranscriptional gene silencing. Proc Natl Acad Sci USA 2008, 105(37):13787-13792.
28. Hashizume R., Ozawa T., Gryaznov S.M., Bollen A.W., Lamborn K.R., Frey W.H., et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008, 10(2):112-120.
29. Koch T. Potent single stranded RNA inhibition. Nucleic Acids Symp Ser 2008, 52:45.
30. Straarup E.M., Fisker N., Hedtjarn M., Lindholm M.W., Rosenbohm C., Aarup V., et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010, 38(20):7100-7111.
31. Obad S., dos Santos C.O., Petri A., Heidenblad M., Broom O., Ruse C., et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011, 43(4):371-378.
32. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452(7189):896-899.
33. Elmen J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008, 36(4):1153-1162.
34. Muller-Kuller T., Capalbo G., Klebba C., Engels J.W., Klein S.A. Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme. Oligonucleotides 2009, 19(3):265-272.
35. Reyes-Gutierrez P., Alvarez-Salas L.M. Cleavage of HPV-16 E6/E7 mRNA mediated by modified 10-23 deoxyribozymes. Oligonucleotides 2009, 19(3):233-242.
36. Naito Y., Yamada T., Ui-Tei K., Morishita S., Saigo K. siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res 2004, 32(Web Server issue):W124-W129.
37. Naito Y., Yoshimura J., Morishita S., Ui-Tei K. siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect. BMC Bioinformatics 2009, 10:392.
38. Ui-Tei K., Naito Y., Saigo K. Guidelines for the selection of effective short-interfering RNA sequences for functional genomics. Methods Mol Biol 2007, 361:201-216.
39. Ui-Tei K., Naito Y., Saigo K. Essential notes regarding the design of functional siRNAs for efficient mammalian RNAi. J Biomed Biotechnol 2006, 2006(4):65052.
40. Judge A.D., Sood V., Shaw J.R., Fang D., Mc Clintock K., Mac Lachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005, 23(4):457-462.
41. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008, 36(7):2136-2151.
42. Watts J.K., Deleavey G.F., Damha M.J. Chemically modified siRNA: tools and applications. Drug Discov Today 2008, 13(19-20):842-855.
43. Stenvang J., Lindow M., Kauppinen S. Targeting of microRNAs for therapeutics. Biochem Soc Trans 2008, 36(Pt 6):1197-1200.
44. Sioud M. Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol 2009, 487:41-59.
45. Mook O.R., Baas F., de Wissel MB, Fluiter K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007, 6(3):833-843.
46. Frieden M., Orum H. The application of locked nucleic acids in the treatment of cancer. IDrugs 2006, 9(10):706-711.
47. Fluiter K., Mook O.R., Baas F. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. Methods Mol Biol 2009, 487:189-203.
48. Paddison P.J., Hannon G.J. RNA interference: the new somatic cell genetics?. Cancer cell 2002, 2(1):17-23.
49. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 2006, 441(7089):111-114.
50. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23(8):1002-1007.
51. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009, 61(9):746-759.
52. Ross J.S., Carlson J.A., Brock G. miRNA: the new gene silencer. Am J Clin Pathol 2007, 128(5):830-836.
53. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64(11):3753-3756.
54. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007, 104(39):15472-15477.
55. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26(5):561-569.
56. Akhtar S., Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007, 117(12):3623-3632.
57. De Paula D., Bentley M.V., Mahato R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13(4):431-456.
58. Gao K., Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2009, 6(3):651-658.
59. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009, 61(9):721-731.
60. Hickerson R.P., Vlassov A.V., Wang Q., Leake D., Ilves H., Gonzalez-Gonzalez E., et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008, 18(4):345-354.
61. Morin A., Gallou-Kabani C., Mathieu J.R., Cabon F. Systemic delivery and quantification of unformulated interfering RNAs in vivo. Curr Top Med Chem 2009, 9(12):1117-1129.
62. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8(2):129-138.
63. Fattal E., Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 2006, 58(11):1203-1223.
64. Pardridge W.M. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004, 4(7):1103-1113.
65. Pardridge W.M. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev 2007, 59(2-3):141-152.
66. Mathupala S.P. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 2009, 19(2):137-140.
67. Akhtar S. Oral delivery of siRNA and antisense oligonucleotides. J Drug Target 2009, 17(7):491-495.
68. Jain K.K. Stability and delivery of RNA via the gastrointestinal tract. Curr Drug Deliv 2008, 5(1):27-31.
69. Tang Q., Li B., Woodle M., Lu P.Y. Application of siRNA against SARS in the rhesus macaque model. Methods Mol Biol 2008, 442:139-158.
70. Cheng K., Mahato R.I. siRNA delivery and targeting. Mol Pharm 2009, 6(3):649-650.
71. Fattal E., Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 2008, 364(2):237-248.
72. Fenske D.B., Chonn A., Cullis P.R. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008, 36(1):21-29.
73. Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expert Opin Drug Deliv 2008, 5(1):25-44.
74. Li S.D., Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 2008, 9(12):1317-1323.
75. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007, 24(3):438-449.
76. Philipp A., Meyer M., Wagner E. Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr Gene Ther 2008, 8(5):324-334.
77. Wu S.Y., Mc Millan N.A. Lipidic systems for in vivo siRNA delivery. AAPS J 2009, 11(4):639-652.
78. Jeong J.H., Mok H., Oh Y.K., Park T.G. siRNA conjugate delivery systems. Bioconjug Chem 2009, 20(1):5-14.
79. Jere D., Arote R., Jiang H.L., Kim Y.K., Cho M.H., Cho C.S. Bioreducible polymers for efficient gene and siRNA delivery. Biomed Mater 2009, 4(2):25020.
80. Kim S.S., Garg H., Joshi A., Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009, 15(11):491-500.
81. Bergelson J.M., Cunningham J.A., Droguett G., Kurt-Jones E.A., Krithivas A., Hong J.S., et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275(5304):1320-1323.
82. Wickham T.J., Mathias P., Cheresh D.A., Nemerow G.R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73(2):309-319.
83. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002, 20(5):446-448.
84. Verma I.M., Somia N. Gene therapy: promises, problems and prospects. Nature 1997, 389(6648):239-242.
85. Kim S.H., Kim S., Robbins P.D. Retroviral vectors. Adv Virus Res 2000, 55:545-563.
86. Young L.S., Searle P.F., Onion D., Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006, 208(2):299-318.
87. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996, 2(9):985-991.
88. Tait D.L., Obermiller P.S., Redlin-Frazier S., Jensen R.A., Welcsh P., Dann J., et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 1997, 3(11):1959-1968.
89. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288(5466):669-672.
90. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987, 84(21):7413-7417.
91. Malone R.W., Felgner P.L., Verma I.M. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989, 86(16):6077-6081.
92. Felgner P.L., Ringold G.M. Cationic liposome-mediated transfection. Nature 1989, 337(6205):387-388.
93. Thanou M., Waddington S., Miller A.D. Gene therapy. Comprehensive medicinal chemistry II 2007, 297-320. Elsevier, Oxford. J.B. Taylor, D.J. Triggle (Eds.).
94. Miller A.D. The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy. Curr Med Chem 2003, 10(14):1195-1211.
95. Kostarelos K., Miller A.D. Synthetic, self-assembly ABCD nanoparticles; A structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev 2005, 34(11):970-994.
96. Miller A.D. Towards safe nanoparticle technologies for nucleic acid therapeutics. Tumori 2008, 94(2):234-245.
97. Miller A.D. Synthetic nucleic acid delivery systems in gene therapy. Encyclopedia of life sciences 2008, Wiley, New York.
98. Carmona S., Jorgensen M.R., Kolli S., Crowther C., Salazar F.H., Marion P.L., et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2009, 6(3):706-717.
99. Mével M., Kamaly N., Carmona S., Oliver M.H., Jorgensen M.R., Crowther C., et al. DODAG: a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Rel 2010, 143:222-232.
100. Kenny G.D., Kamaly N., Kalber T.L., Brody L.P., Sahuri M., Shamsaei E., et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Rel 2011, 149:111-116.
101. Li S.D., Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788(10):2259-2266.
102. Chono S., Li S.D., Conwell C.C., Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 2008, 131(1):64-69.
103. Aleku M., Schulz P., Keil O., Santel A., Schaeper U., Dieckhoff B., et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008, 68(23):9788-9798.
104. Abrams M.T., Koser M.L., Seitzer J., Williams S.C., DiPietro M.A., Wang W., et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther 2010, 18(1):171-180.
105. Semple S.C., Akinc A., Chen J., Sandhu A.P., Mui B.L., Cho C.K., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28(2):172-176.
106. Sato Y., Murase K., Kato J., Kobune M., Sato T., Kawano Y., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008, 26(4):431-442.
107. Iwami K., Natsume A., Wakabayashi T. Gene therapy for high-grade glioma. Neurol Med Chir (Tokyo) 2010, 50(9):727-736.
108. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
109. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003.
110. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1997, 57(17):3672-3677.
111. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997, 17(9):5612-5619.
112. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59(4):793-797.
113. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054.
114. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003, 13(2):176-184.
115. 6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 2000, 60(20):5815-5824.
116. Liu L., Markowitz S., Gerson S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996, 56(23):5375-5379.
117. Gerson S.L. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4):296-307.
118. 6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21(2):135-140.
119. Belanich M., Pastor M., Randall T., Guerra D., Kibitel J., Alas L., et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56(4):783-788.
120. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a southwest oncology group study. J Clin Oncol 1998, 16(10):3310-3315.
121. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16(12):3851-3857.
122. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 1999, 5(4):807-814.
123. Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006, 12(2):328-331.
124. Kanzawa T., Bedwell J., Kondo Y., Kondo S., Germano I.M. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 2003, 99(6):1047-1052.
125. Quinn J.A., Pluda J., Dolan M.E., Delaney S., Kaplan R., Rich J.N., et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002, 20(9):2277-2283.
126. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2005, 23(28):7178-7187.
127. Bidros D.S., Liu J.K., Vogelbaum M.A. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 2010, 6(1):117-125.
128. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994, 91(6):2076-2080.
129. Lieberman D.M., Laske D.W., Morrison P.F., Bankiewicz K.S., Oldfield E.H. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995, 82(6):1021-1029.
130. Krauze M.T., Saito R., Noble C., Tamas M., Bringas J., Park J.W., et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005, 103(5):923-929.
131. Oh S., Odland R., Wilson S.R., Kroeger K.M., Liu C., Lowenstein P.R., et al. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 2007, 107(3):568-577.
132. Sampson J.H., Raghavan R., Brady M.L., Provenzale J.M., Herndon J.E., Croteau D., et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007, 9(3):343-353.
133. Mardor Y., Roth Y., Lidar Z., Jonas T., Pfeffer R., Maier S.E., et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001, 61(13):4971-4973.
134. Sadelain M., Riviere I., Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003, 3(1):35-45.
135. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8(4):299-308.
136. Morgan R.A., Dudley M.E., Yu Y.Y., Zheng Z., Robbins P.F., Theoret M.R., et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003, 171(6):3287-3295.
137. Abad J.D., Wrzensinski C., Overwijk W., De Witte M.A., Jorritsma A., Hsu C., et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother 2008, 31(1):1-6.
138. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
139. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
140. Viola A., Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996, 273(5271):104-106.
141. Stauss H.J., Cesco-Gaspere M., Thomas S., Hart D.P., Xue S.A., Holler A., et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther 2007, 15(10):1744-1750.
142. Thomas S., Xue S.A., Cesco-Gaspere M., San Jose E., Hart D.P., Wong V., et al. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol 2007, 179(9):5803-5810.
143. Cohen C.J., Li Y.F., El-Gamil M., Robbins P.F., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007, 67(8):3898-3903.
144. Kuball J., Dossett M.L., Wolfl M., Ho W.Y., Voss R.H., Fowler C., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007, 109(6):2331-2338.
145. Sommermeyer D., Neudorfer J., Weinhold M., Leisegang M., Engels B., Noessner E., et al. Designer T cells by T cell receptor replacement. Eur J Immunol 2006, 36(11):3052-3059.
146. Heemskerk M.H., Hagedoorn R.S., van der Hoorn M.A., van der Veken L.T., Hoogeboom M., Kester M.G., et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007, 109(1):235-243.
147. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006, 66(17):8878-8886.
148. Li A., Walling J., Ahn S., Kotliarov Y., Su Q., Quezado M., et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009, 69(5):2091-2099.
149. Nutt C.L., Mani D.R., Betensky R.A., Tamayo P., Cairncross J.G., Ladd C., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003, 63(7):1602-1607.
150. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., de Rooi J.J., Stubbs A.P., Duijm J.E., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009, 69(23):9065-9072.
151. Freije W.A., Castro-Vargas F.E., Fang Z., Horvath S., Cloughesy T., Liau L.M., et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004, 64(18):6503-6510.